Multiply Labs has raised $75 Million in New Funding

According to filings with the U.S. Securities and Exchange Commission, Multiply Labs has raised $75 Million in new Series B funding. The federal securities law requires the notice to be filed by...

Craig Etkin

November 11, 2026 2 Min Read

63 0

According to filings with the U.S. Securities and Exchange Commission, Multiply Labs has raised $75 Million in new Series B funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Dr. Patrick Soon-Shiong, NantWorks, AstraZeneca, Lingotto, Teradyne, Strange Ventures, Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund

About Multiply Labs
Multiply Labs develops robotic biomanufacturing infrastructure for advanced biological therapies. Its physical AI platform uses robots, software, automated unit operations, and real-time monitoring to create closed, sterile, scalable manufacturing systems. The companys Robotic Cluster connects existing GMP instruments into one autonomous system, allowing manufacturers to preserve their validated processes while increasing throughput by up to 100 times and reducing costs by 74%. Its software records sensor readings and process interactions in real time, produces electronic records, supports 21 CFR Part 11 compliance, and integrates with existing quality systems. Multiply Labs positions its technology as a solution to the scale, complexity, cost, reliability, sterility, and traceability challenges facing modern biomanufacturing. The company is based in San Francisco and announced a $75 million Series B led by NantWorks, with participation from AstraZeneca, Lingotto, and others.

To learn more, visit https://www.multiplylabs.com/
Linkedin: https://www.linkedin.com/company/multiply-labs/

Contact:
Fred Parietti, CEO
https://www.linkedin.com/in/fred-parietti/